EZH2 and diffuse large B-cell lymphoma: The oral EZH2 inhibitor Tazemetostat has shown positive results as a single agent in a phase 2 clinical trial for relapsed or refractory FL[12] and a phase 2 study investigating clinical activity in DLBCL is underway (NCT01897571).